- Enoxaparin
drugbox
IUPAC_name = 6- [5-acetylamino-4,6-dihydroxy-2- (sulfooxymethyl)tetrahydropyran-3-yl] oxy-3- [5-(6-carboxy-4,5-dihydroxy-3- sulfooxy-tetrahydropyran-2-yl)oxy-6-(hydroxymethyl)- 3-sulfoamino-4-sulfooxy-tetrahydropyran-2-yl] oxy-4-hydroxy-5-sulfooxy-tetrahydropyran-2- carboxylicacid
width = 300px
CAS_number = 9005-49-6
ChemSpiderID = 751
ATC_prefix = B01
ATC_suffix = AB05
ATC_supplemental =
PubChem = 772
DrugBank = APRD00068
chemical_formula = (C26H40N2O36S5)n
molecular_weight = 4500 daltons (average)
bioavailability = 92%
protein_bound = 80% bound-albumin
metabolism = primarily by liver by desulfation and/or depolymerization
elimination_half-life = 4.5 hours
pregnancy_category = B
legal_UK = POM
legal_US = Rx-only
legal_status =
routes_of_administration = Subcutaneous (SC) Injection and intervenous (IV) per package insertEnoxaparin is a
low molecular weight heparin manufactured bySanofi-Aventis . It is marketed as Lovenox or Clexane. Enoxaparin injections are derived from the intestinal mucosa of pigs.Enoxaparin is used to prevent and treatdeep vein thrombosis orpulmonary embolism , and is given as asubcutaneous injection (by a health care provider or the patient). Its use is evolving inacute coronary syndrome s (ACS).Indications
In the UK, enoxaparin is approved for five indications:
* The prophylaxis ofthromboembolism disorders of venous origin, in particular those which may be associated withorthopaedic surgery . There is limited evidence supporting the use of enoxaparin in orthoapedic patients [Warwick D, Williams MH, Bannister GC. Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis. J Bone Joint Surg Br. 1995 Jan;77(1):6-10. PMID 7822397] , although evidence is reasonable for colorectal patients [Bergqvist D. Venous thromboembolism: a review of risk and prevention in colorectal surgery patients. Dis Colon Rectum. 2006 Oct;49(10):1620-8. PMID 17019655]
* The prophylaxis of venous thromboembolism (VTE) in medical patients bedridden due to acuteillness .
* The treatment of venous thromboembolism disease (VTED) presenting withdeep vein thrombosis (DVT),pulmonary embolism (PE) or both.
* The treatment of unstable angina (UA) and non-Q-wavemyocardial infarction (NQMI), administered concurrently withaspirin .
* The prevention of thrombus formation in the extracorporeal circulation duringhaemodialysis . In theUnited States , enoxaparin is FDA approved for eight indications:
* Prophylaxis of DVT in medically ill patient,
* Total hip & knee replacement,
* Extended hip-replacement,
* Abdominal surgery.
* Treatment of DVT with or without PE inpatient and
* Treatment of DVT inpatient, with ACS, including STEMI.Mechanism of action
Enoxaparin binds to and accelerates the activity of
antithrombin III . By activating antithrombin III, enoxaparin preferentially potentiates the inhibition ofcoagulation factors Xa and IIa. The anticoagulant effect of enoxaparin can be directly correlated to its ability to inhibitfactor Xa . Factor Xa catalyzes the conversion of prothrombin tothrombin , so enoxaparin’s inhibition of this process results in decreased thrombin and ultimately the prevention offibrin clot formation.=Monitoring=
* Enoxaparin does not affect the INR, PT or aPTT
* Anti-factor Xa levels can be measured, and are often used to monitor enoxaparin activityPregnancy
* Category B: enoxaprin is safe for use in the
second trimester as it does not cross theplacenta and safe while breast feedingide effects
*
Bleeding [Warwick D, Bannister GC, Glew D, Mitchelmore A, Thornton M, Peters TJ, Brookes S. Perioperative low-molecular-weight heparin. Is it effective and safe. J Bone Joint Surg Br. 1995 Sep;77(5):715-9. PMID 7559695]
*Thrombocytopenia , i.e. can be associated withheparin-induced thrombocytopenia (0.5-5.0% of patients treated for at least five days [Levy JH, Tanaka KA, Hursting MJ. Reducing thrombotic complications in the perioperative setting: an update on heparin-induced thrombocytopenia. Anesth Analg. 2007 Sep;105(3):570-82. PMID 17717208]
*Pain ,bruising orirritation ; hard, inflamednodule s or an itchy redrash at the injection site
* Symptoms similar to those ofhayfever
* Abdominal/chest pain
*Headache Reversal Agent
*
Protamine , although not as effective at reversal as it is for heparin due to more activity at the Xa clotting factor (enoxaparin); as heparin has both Xa and IIa. Protamine sulfate will reverse enoxaparin by 66% per package insert.Availability
100 mg/mL
* Prefilled Syringes: 30mg/0.3mL, 40mg/0.4mL
* Graduated Prefilled Syringes: 60mg/0.6mL, 80mg/0.8mL, 100mg/1mL, 120mg/0.8mL, 150mg/1mL* Multiple Dose Vials: 300mg/3.0mL150mg/mL
References
External links
* [http://redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi?CARD=APRD00068 DrugBank Information]
* [http://en.sanofi-aventis.com/group/products/p_group_products_cardio_lovenox.asp Sanofi-Aventis information]
* [http://products.sanofi-aventis.us/lovenox/lovenox.html Lovenox: Prescribing Information]
Wikimedia Foundation. 2010.